Complix is at the forefront of biopharmaceutical innovation with its proprietary Cell Penetrating Alphabody (CPAB) technology, which enables the development of therapeutics targeting intracellular disease mechanisms that are typically deemed "undruggable" by conventional methods. This technology allows CPABs to penetrate human cells and selectively modulate protein interactions within the cytosol and nucleus, addressing a wide array of disease targets, particularly in oncology, autoimmunity, and viral diseases. By leveraging the unique structural properties of CPABs, Complix aims to create a new class of therapeutics that can effectively reach and interact with intracellular targets, which are often inaccessible to traditional antibodies and small molecules.

The company's pipeline includes several promising candidates that focus on previously challenging targets, such as transcription factors involved in cancer cell growth and differentiation. Complix is also actively pursuing anti-viral therapeutics, including a program aimed at developing CPABs that inhibit viral entry, specifically targeting conserved epitopes of viral fusion proteins. With a strong intellectual property position and a commitment to rapid development, Complix is poised to deliver transformative therapies that address significant unmet medical needs, potentially revolutionizing treatment options for various diseases.

Belgium

A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.

Complix

Company Details